drugset / Trial / NCT00427011
A Study of E2007 In Patients With Parkinson's Disease
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Phase IIb open-label extension study for patients with Parkinson's Disease. All patients will receive active study drug. The study will involve outpatient visits only. Patients who completed Study E2007-A001-214 (Cohorts I and II) and who meet inclusion/exclusion criteria will be enrolled and enter the 12-week Titration Phase (from "Dispense Study Drug" at Week 0 \[Visit 2\] through Week 12 \[Visit 7\]) followed by the Maintenance Phase (from Week 12 \[Visit 7\] to end of study).
Timeline
- Start
- 2007-02
- Primary completion
- 2008-04
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Perampanel | Small molecule | 2 mg | Oral |
| Subject | Perampanel | Small molecule | 4 mg | Oral |
| Subject | Perampanel | Small molecule | 6 mg | Oral |
| Subject | Perampanel | Small molecule | 8 mg | Oral |